Novo Nordisk To Acquire Forma Therapeutics And Expand Presence In Sickle Cell Disease And Rare Blood Disorders
Novo Nordisk To Acquire Forma Therapeutics And Expand Presence In Sickle Cell Disease And Rare Blood Disorders
09/01/22, 12:04 PM
Location
denmarkIndustry
science and engineering
biopharma
therapeutics
pharmaceutical
biotechnology
health care
Novo Nordisk and Forma Therapeutics, Holdings Inc. (Nasdaq: FMTX) today announced that they have entered into a definitive agreement under which Novo Nordisk will acquire Forma Therapeutics for $20 per share in cash, which represents a total equity value of $1.1 billion. Forma Therapeutics is a clinical-stage biopharmaceutical company focused on transforming the lives of patients with sickle cell disease (SCD) and rare blood disorders.
Company Info
Location
Denmark
Company info
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,000 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube.